--- title: "CSL (CSL) news: class action" url: "https://aibio.space/companies/csl/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CSL class action news. CSL news for investors: CSL is an Australian biotech company that makes medicines from donated human plasma, flu vaccines through CSL…" --- Desk view · Opinion · Updated Oct 22, 2026 ## CSL resets around plasma as Vifor shrinks CSL is a steady plasma business recovering from a costly reset, with $7.1 billion of FY26 impairments and a modest FY27 outlook. The plasma side looks stable, but growth depends on cutting collection costs and replacing Vifor's lost sales under a new chief executive. Read the full desk view aibio.space Investor Rank · Opinion **5** /10 Neutral view The plasma business still generates cash, but a $2.6 billion loss, a guidance cut, shrinking Vifor and a pipeline the chair says did not deliver weigh heavily. - **Technology**: 2/2 - **Odds**: 0/2 - **Balance sheet**: 2/2 - **Risk**: 1/2 - **Momentum**: 0/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Mature plasma platform.** Immunoglobulin, albumin and clotting factors drive most sales, with newer drugs Hemgenix and Andembry growing from a small base. - **Odds**: **Thin pipeline.** The chair said CSL's R&D did not deliver, and the newest program, lixudebart, is in phase 2. - **Balance sheet**: **Solid cash generation.** Operating cash flow was $3.5 billion in FY26 and leverage 1.8 times, enough to fund the dividend and an A$1.1 billion buyback. - **Main risk**: **Shrinking Vifor and policy pressure.** Vifor revenue is guided down about 25% in FY27, and U.S. pricing agreements cap future launch prices. - **Watch next**: **Leadership and margins.** The Oct. 27 AGM, Deborah Waterhouse's start on Feb. 1, 2027 and progress on plasma collection costs. ## Top news on CSL 1. 2026-10-22 Legal [CSL faces shareholder class action over FY26 guidance and disclosure](https://aibio.space/news/csl-faces-shareholder-class-action-fy26-guidance-disclosure/) The suit, filed in the Supreme Court of Victoria, covers investors who bought CSL securities between February 2025 and May 2026. CSL denies liability and says it will defend the case. ## Dates **27 October 2026** Annual general meeting in Melbourne [Source](https://announcements.asx.com.au/asxpdf/20260917/pdf/0745r5xv26f9y2.pdf) **1 February 2027** Deborah Waterhouse becomes CEO and managing director [Source](https://newsroom.csl.com/2026-10-21-CSL-appoints-Deborah-Waterhouse-as-CEO-Managing-Director) **Mid-2027** Start of clinical trials for Horizon 2 immunoglobulin manufacturing [Source](https://announcements.asx.com.au/asxpdf/20260729/pdf/07257sm52ttd3q.pdf) **By end of 2027** Rollout of Haemonetics plasmapheresis platform across U.S. collection centres [Source](https://announcements.asx.com.au/asxpdf/20261008/pdf/0753hvwwh91d7n.pdf) ## The money Cash and cash equivalents of $1,513 million at June 30, 2026, with leverage of 1.8 times net debt to EBITDA. CSL priced $1.5 billion of bonds on Oct. 7, 2026 to refinance debt. [Source](https://announcements.asx.com.au/asxpdf/20260818/pdf/072vppn8s55bwq.pdf) FY26 (year to June 30, 2026) total revenue of $15.8 billion, down 1% at constant currency; CSL reports half-yearly. FY27 guidance: revenue in line with FY26, underlying NPAT up about 5%. [Source](https://announcements.asx.com.au/asxpdf/20260818/pdf/072vps0nphgdnj.pdf) ## Risks on the record - CSL Vifor expects FY27 revenue to fall about 25% because of generic iron competition, the end of Velphoro's TDAPA period and the EU revocation of Tavneos. [Source](https://announcements.asx.com.au/asxpdf/20260818/pdf/072vps0nphgdnj.pdf) - A shareholder group proceeding filed in October 2026 alleges breaches of disclosure obligations over FY26 guidance; CSL denies liability. [Source](https://announcements.asx.com.au/asxpdf/20261022/pdf/075mkm99xb7rjc.pdf) - Under U.S. agreements, CSL will give Medicaid prices comparable to other developed countries and price new launches similarly for all U.S. payers. [Source](https://newsroom.csl.com/2026-08-31-CSL-Enters-Agreements-with-the-U-S-Government-to-Lower-Drug-Prices-and-Support-Investment-in-U-S-Manufacturing) ## Questions investors ask ### What is aibio.space's Investor Rank for CSL? 5 out of 10, our neutral view. The plasma business still generates cash, but a $2.6 billion loss, a guidance cut, shrinking Vifor and a pipeline the chair says did not deliver weigh heavily. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### Who is CSL's new CEO? CSL appointed Deborah Waterhouse, CEO of ViiV Healthcare since 2017, as CEO and managing director from Feb. 1, 2027. Gordon Naylor remains interim CEO until then. [Source](https://newsroom.csl.com/2026-10-21-CSL-appoints-Deborah-Waterhouse-as-CEO-Managing-Director) ### Why did CSL report a loss for FY26? CSL booked $7.1 billion of pre-tax impairments and $799 million of restructuring costs in FY26, producing a reported net loss of $2.6 billion. Underlying NPATA was $3.1 billion, down 2%. [Source](https://announcements.asx.com.au/asxpdf/20260818/pdf/072vps0nphgdnj.pdf) ### What is CSL's FY27 guidance? CSL expects FY27 revenue in line with FY26 and underlying NPAT growth of about 5% at FY26 exchange rates. CSL Vifor revenue is expected to fall about 25%. [Source](https://announcements.asx.com.au/asxpdf/20260818/pdf/072vps0nphgdnj.pdf) ### Why was Tavneos withdrawn in Europe? The European Commission revoked Tavneos' EU authorization after an EMA review found the main ADVOCATE trial breached good clinical practice and its data could no longer be relied on. [Source](https://www.ema.europa.eu/en/documents/referral/tavneos-article-20-procedure-ema-recommends-revoking-marketing-authorisation-tavneos_en.pdf) ### What is the CSL class action about? A group proceeding filed in the Supreme Court of Victoria in October 2026 covers people who acquired CSL securities between Feb. 11, 2025 and May 11, 2026 and alleges disclosure breaches. CSL denies liability. [Source](https://announcements.asx.com.au/asxpdf/20261022/pdf/075mkm99xb7rjc.pdf) ### What is the latest CSL (CSL) stock news? Our latest story on CSL, dated Oct 22, 2026: "CSL faces shareholder class action over FY26 guidance and disclosure". The suit, filed in the Supreme Court of Victoria, covers investors who bought CSL securities between February 2025 and May 2026. CSL denies liability and says it will defend the case. [Source](https://aibio.space/news/csl-faces-shareholder-class-action-fy26-guidance-disclosure/) ### Where is CSL headquartered? SEC records list its business address as 45 POPLAR RD, PRAKVILLE VICTORIA AUSTRA, Australia, 00000. Source ### How can I follow CSL (CSL) news? Press Follow on this page to add CSL to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming CSL so far, in Legal. Source ## Legal and investor matters Checked against CSL filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. 1. 2026-10-22 Class action Shareholder group proceeding filed against CSL in Victorian Supreme Court CSL told the ASX on 2026-10-22 that it was notified late on 2026-10-21 of a group proceeding in the Supreme Court of Victoria naming CSL as defendant. It is brought for people who acquired interests in certain CSL securities between 2025-02-11 and 2026-05-11. The proceeding alleges breaches of continuous disclosure obligations and representations about medium-term performance and FY26 outlook. CSL denies liability and says it will defend the proceeding. Supreme Court of Victoria · Status: filed [CSL ASX announcement, 2026-10-22](https://investorpa.com/announcement-pdf/20261022/360497.pdf) 2. 2026-10-21 Governance CSL names Deborah Waterhouse as CEO from 2027-02-01 CSL announced on 2026-10-21 that its board appointed Deborah Waterhouse as Chief Executive Officer and Managing Director, effective 2027-02-01. She has been CEO of ViiV Healthcare since 2017. In February 2026 CSL announced that Paul McKenzie would retire, with Gordon Naylor appointed interim CEO from 2026-02-11; Naylor continues as interim CEO until 2027-02-01. The chair said the board's decision was unanimous. An attachment to the announcement sets out key employment terms, including a base salary of GBP 1,500,000 per annum. [CSL ASX announcement, 2026-10-21](https://investorpa.com/announcement-pdf/20261021/360240.pdf) 3. 2026-08-18 Other CSL reports FY26 statutory loss after US$7.9 billion of restructuring and impairment expenses CSL reported results for the year ended 2026-06-30 showing a reported net loss after tax attributable to members of US$2,579 million, against a profit of US$3,002 million a year earlier. The annual report states that restructuring and impairment expenses totaled US$7,923 million. Underlying NPATA was US$3,098 million. The annual report also records a further A$1.15 billion share buy-back program. [CSL Annual Report 2025/26 (ASX, 2026-08-18)](https://announcements.asx.com.au/asxpdf/20260818/pdf/072vppn8s55bwq.pdf) 4. 2026-06-29 Regulatory CHMP recommends revoking EU authorisation for Tavneos sold by CSL Vifor CSL told the ASX that on 2026-06-26 the EMA's CHMP recommended revoking the EU marketing authorisation for Tavneos (avacopan), following an Article 20 review of data handling in the ADVOCATE trial. CSL expected to stop new patient starts in the EU and EEA and put FY26 Tavneos sales at about $145 million. The annual report says the European Commission later revoked the authorisation and records a $166 million Tavneos charge. [CSL ASX announcement, 2026-06-29](https://announcements.asx.com.au/asxpdf/20260629/pdf/0713m82rbl5yrk.pdf) 5. 2026-05-11 Other CSL cuts FY26 outlook and flags about $5 billion of further impairments On 2026-05-11 interim CEO Gordon Naylor presented a 90 day review and revised FY26 guidance down to revenue of around $15.2 billion and NPATA of around $3.1 billion. CSL cited US immunoglobulin channel inventory, albumin in China and other items. It said it expected about $5 billion of additional non-cash pre-tax impairments across FY26 and FY27. Chief Commercial Officer Andy Schmeltz was also to retire. [CSL ASX announcement, 2026-05-11](https://announcements.asx.com.au/asxpdf/20260511/pdf/06zfvkkjj67msw.pdf) 6. 2026-02-10 Governance CSL CEO Paul McKenzie retires; Gordon Naylor named interim CEO CSL announced on 2026-02-10 that Chief Executive Officer and Managing Director Paul McKenzie would retire, with former executive and director Gordon Naylor appointed interim CEO from 2026-02-11. The chair said the board had determined that now was the right time for new leadership. McKenzie's existing awards would be treated under their original terms. A search for a permanent CEO began at that time. [CSL ASX announcement, 2026-02-10](https://announcements.asx.com.au/asxpdf/20260210/pdf/06w50ddsl71vnj.pdf) ## Pipeline | Program | Indication | Stage | |---|---|---| | Lixudebart (anti-claudin-1, with Alentis) | ANCA-associated vasculitis with rapidly progressive glomerulonephritis; FSGS; PSC | Phase 2 RENAL trial; phase 3 planned [Source](https://newsroom.csl.com/2026-10-04-CSL-and-Alentis-announce-global-partnership-to-develop-and-commercialise-lixudebart-for-rare-kidney-and-liver-diseases) | | Clazakizumab (anti-IL-6) | Cardiovascular events in end-stage kidney disease | Phase 3; licensed to Eli Lilly for other indications [Source](https://announcements.asx.com.au/asxpdf/20260818/pdf/072vq7zfyd3zhp.pdf) | | VMX-C001 (with VarmX) | Restoring blood coagulation | Phase 3 trial commenced in FY26 [Source](https://announcements.asx.com.au/asxpdf/20260818/pdf/072vq7zfyd3zhp.pdf) | | Horizon 2 immunoglobulin manufacturing process | Higher immunoglobulin yield from plasma | Clinical trials expected to start mid-2027 before FDA and EMA approval [Source](https://announcements.asx.com.au/asxpdf/20260729/pdf/07257sm52ttd3q.pdf) | | Andembry (garadacimab) | Hereditary angioedema | Marketed; $240 million of sales in first full year (FY26) [Source](https://announcements.asx.com.au/asxpdf/20260818/pdf/072vps0nphgdnj.pdf) | ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open ASX:CSL on TradingView](https://www.tradingview.com/symbols/ASX-CSL/). ## SEC filings and registration - **SEC name**: Csl Ltd - **CIK**: 1274152 - **US tickers**: CSLLY (OTC), CMXHF (OTC) - **Business address**: 45 POPLAR RD, PRAKVILLE VICTORIA AUSTRA, Australia, 00000 - **Phone**: 61-3-9389-1911 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001274152), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/csl/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "CSL (CSL) news: class action", 2026-10-31, https://aibio.space/companies/csl/